(Press-News.org) A study by researchers in Nottingham has developed a new clinical test for breast cancer which aims to improve patient treatment.
The Nottingham Prognostic Index Plus (NPI+) could be available to patients within two years.
The findings, published in the British Journal of Cancer today, could significantly improve the way in which breast cancer patients are treated by giving clinicians more detailed information about a patient's breast cancer type and its likely behaviour, which will help them create a more personalised treatment plan.
The research, funded by the Medical Research Council, was led by Professor Ian Ellis in The University of Nottingham's Division of Cancer and Stem Cells, in collaboration with colleagues at Nottingham University Hospitals NHS Trust and Nottingham Trent University's John van Geest Cancer Research Centre.
The current Nottingham Prognostic Index (NPI) was developed over 30 years ago and is a world-recognised tool used by clinicians treating patients with breast cancer to decide on the risk of the disease returning. However, breast cancer is now known to be a biologically complex disease and its various forms can have very different outcomes so the more information that doctors have about each patient's cancer, the better they can plan effective treatments. The new NPI+ test has been developed from the existing NPI by incorporating the measurement of 10 proteins (biomarkers) found in breast cancer cells. These biomarkers include ER and HER2, the two biomarkers currently tested for in clinics, but also others that are not currently tested.
This paper is a follow on from initial research published in the British Journal of Cancer in October last year in which the team described seven classes of breast cancer using those ten biomarkers. It has taken these seven classes of breast cancer and has incorporated other factors in order to develop the NPI+, which can be used in all breast cancer patients to give a more accurate prognosis than is currently available.
Professor Ian Ellis says "Using a panel of 10 biomarkers and other clinical information, we are able to categorise women with breast cancer into one of seven treatment-specific classes based on their personal cancer biology. We believe the categorisation of women with breast cancer into more specific risk classes will deliver better targeting of relevant therapies, which will result in improved outcomes with reduced costs and less anxiety for the patient.
NPI+ will reduce uncertainty for clinicians and patients by removing a large number of patients with indeterminate prognosis and allow better-informed treatment decisions. In addition the ability to give survival prediction will be welcomed by concerned patients. Decisions can be made more quickly reducing waiting times and unnecessary consultation time."
The NPI+ test was developed using over 1,000 breast cancer samples and was shown to predict both patient survival and also those patients at risk of treatment failure which can help doctors to consider additional forms of treatment to improve survival. Importantly, the technology required to measure protein biomarkers in tumour samples is already in place in most pathology laboratories across the UK, whereas newly developed genetic profiling tests need to be sent to specialist laboratories, which brings additional costs and time delays.
It is anticipated with some further validation work that the NPI+ test could be ready for use in the clinic in as little as two years.
INFORMATION: END
New prognostic test for breast cancer could improve patient treatment
2014-03-12
ELSE PRESS RELEASES FROM THIS DATE:
The first food web inside humans suggests potential new treatments for infection
2014-03-12
Imagine going to the doctor with an infection and being sent home with a course of drugs. Unknown to your doctor you actually have two infections. If you take the drugs will the other infection go away by itself? What if you take the drugs and the other infection gets worse? This quandary faces those treating patients with multiple infections.
A new study led by former University of Sheffield PhD student Dr Emily Griffiths, in collaboration with the universities of Edinburgh, Liverpool and Zürich, has taken a novel approach to understanding this problem, shedding light ...
Experts urge Chancellor to 'crack down on cheap drink' in next week's budget
2014-03-12
Writing on bmj.com, Katherine Brown, Director at the Institute of Alcohol Studies, says the UK chancellor should resist industry lobbying to scrap the annual rise in alcohol duty because "society simply can't afford for such cheap drink to get cheaper."
The duty escalator has been in place since 2008 to ensure that the price of alcohol rises at 2% above inflation. But a campaign by the wine and spirits industry is calling on the Chancellor to "Be Fair George!" and scrap the duty escalator for all alcohol in this year's budget.
Last year, following a similar campaign ...
Nicotine patches do not appear to help pregnant smokers to quit
2014-03-12
Smoking during pregnancy increases the risk of adverse pregnancy and birth outcomes and may have long lasting effects in offspring.
In England, 26% of women smoke in the year before their pregnancy and 12% smoke through to delivery. The rate is similar or even higher in other high income countries.
Guidelines suggest adding nicotine replacement therapies (NRT) to behavioural smoking cessation support in pregnant smokers because of their excellent safety profile and proved effectiveness in other groups of smokers. However, there is a lack of good quality evidence on ...
Community action not enough to reduce problem drinking and related harms
2014-03-11
Implementation of community-based interventions alone is unlikely to be effective for reducing most alcohol-related harms and risky alcohol consumption, according to a study by Australian researchers published in this week's PLOS Medicine. Anthony Shakeshaft and colleagues from the National Drug and Alcohol Research Centre at UNSW (University of New South Wales), report that alcohol-related crime, road-traffic crashes, and hospital inpatient admissions did not differ between communities that did and did not implement community-based interventions.
The researchers reached ...
Crowdsourced rain samples map Hurricane Sandy's evolution
2014-03-11
A unique method to collect rain water samples during Hurricane Sandy has revealed the storm's chemical "signature" with a new level of detail. The technique may also lead to weather model advances that will ultimately improve storm prediction, say researchers at the University of Utah whose study was published online today in PLOS ONE.
Hurricane Sandy, also known as Superstorm Sandy, was the deadliest and most destructive hurricane of the 2012 Atlantic hurricane season, according to government sources. Damage estimates exceed $65 billion and nearly 300 people perished ...
Lignin breakthroughs serve as GPS for plant research
2014-03-11
Researchers at North Carolina State University have developed the equivalent of GPS directions for future plant scientists to understand how plants adapt to the environment and to improve plants' productivity and biofuel potential.
Two articles published March 11 in The Plant Cell offer a step-by-step approach for studying plant traits, drawing on comprehensive, quantitative research on lignin formation in black cottonwood. Lignin, an important and complex polymer responsible for plant growth and development, provides mechanical strength and water transport that enables ...
Antibody could be used to target tumor-causing protein, study shows
2014-03-11
CINCINNATI—Cincinnati Cancer Center (CCC) and University of Cincinnati (UC) Cancer Institute researchers have found in a phase-1 study that patients with advanced melanoma and kidney cancer who were treated with a certain antibody that targets a tumor-enhancing protein was safe, which could lead to more treatment options for patients.
The study is published in the March 11 edition of PLOS ONE, a peer-reviewed, open access online publication.
Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader ...
Examining potential of clinical applications of whole-genome sequencing
2014-03-11
In an exploratory study involving 12 adults, the use of whole-genome sequencing (WGS) was associated with incomplete coverage of inherited-disease genes, low reproducibility of detection of genetic variation with the highest potential clinical effects, and uncertainty about clinically reportable findings, although in certain cases WGS will identify genetic variants warranting early medical intervention, according to a study in the March 12 issue of JAMA.
As technical barriers to human DNA sequencing decrease and costs approach $1,000, whole-genome sequencing (WGS) is ...
Discrepancies between trial results reported on clinical trial registry and in journals
2014-03-11
During a one year period, among clinical trials published in high-impact journals that reported results on a public clinical trial registry (ClinicalTrials.gov), nearly all had at least 1 discrepancy in the study group, intervention, or results reported between the 2 sources, including discrepancies in the designated primary end points for the studies, according to a study in the March 12 issue of JAMA.
The 2007 Food and Drug Administration (FDA) Amendments Act expanded requirements for ClinicalTrials.gov, mandating results reporting within 12 months of trial completion ...
Study finds comparable outcomes for commonly used surgeries to treat vaginal prolapse
2014-03-11
For women undergoing surgery for vaginal prolapse and stress urinary incontinence, neither of 2 common repair procedures was superior to the other for functional or adverse event outcomes, and behavioral therapy with pelvic muscle training did not improve urinary symptoms or prolapse outcomes after surgery, according to a study in the March 12 issue of JAMA.
Pelvic organ prolapse (protrusion) occurs when the uterus descends into the lower vagina or vaginal walls protrude beyond the vaginal opening, and can occur as a result of childbirth. Approximately 300,000 surgeries ...